BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pooja D, Gunukula A, Gupta N, Adams DJ, Kulhari H. Bombesin receptors as potential targets for anticancer drug delivery and imaging. The International Journal of Biochemistry & Cell Biology 2019;114:105567. [DOI: 10.1016/j.biocel.2019.105567] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Rurarz BP, Bukowczyk M, Gibka N, Piastowska-Ciesielska AW, Karczmarczyk U, Ulański P. Nanostrategies for Therapeutic and Diagnostic Targeting of Gastrin-Releasing Peptide Receptor. Int J Mol Sci 2023;24. [PMID: 36834867 DOI: 10.3390/ijms24043455] [Reference Citation Analysis]
2 Gong L, Zhao H, Liu Y, Wu H, Liu C, Chang S, Chen L, Jin M, Wang Q, Gao Z, Huang W. Research advances in peptide‒drug conjugates. Acta Pharmaceutica Sinica B 2023. [DOI: 10.1016/j.apsb.2023.02.013] [Reference Citation Analysis]
3 Alhaj-Suliman SO, Wafa EI, Salem AK. Engineering nanosystems to overcome barriers to cancer diagnosis and treatment. Adv Drug Deliv Rev 2022;189:114482. [PMID: 35944587 DOI: 10.1016/j.addr.2022.114482] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Desai P, Rimal R, Sahnoun SEM, Mottaghy FM, Möller M, Morgenroth A, Singh S. Radiolabeled Nanocarriers as Theranostics—Advancement from Peptides to Nanocarriers. Small. [DOI: 10.1002/smll.202200673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Calatayud DG, Neophytou S, Nicodemou E, Giuffrida SG, Ge H, Pascu SI. Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers. Front Chem 2022;10:830133. [DOI: 10.3389/fchem.2022.830133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Moody TW, Lee L, Ramos-Alvarez I, Iordanskaia T, Mantey SA, Jensen RT. Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy. Front Endocrinol (Lausanne) 2021;12:728088. [PMID: 34539578 DOI: 10.3389/fendo.2021.728088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
7 Dash BS, Lu YJ, Chen HA, Chuang CC, Chen JP. Magnetic and GRPR-targeted reduced graphene oxide/doxorubicin nanocomposite for dual-targeted chemo-photothermal cancer therapy. Mater Sci Eng C Mater Biol Appl 2021;128:112311. [PMID: 34474862 DOI: 10.1016/j.msec.2021.112311] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
8 Pretze M, Reffert L, Diehl S, Schönberg SO, Wängler C, Hohenberger P, Wängler B. GMP-compliant production of [68Ga]Ga-NeoB for positron emission tomography imaging of patients with gastrointestinal stromal tumor. EJNMMI Radiopharm Chem 2021;6:22. [PMID: 34228236 DOI: 10.1186/s41181-021-00137-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pretze M, Wängler C, Schönberg SO, Wängler B. 68Ga-NeoB: Präklinische Ergebnisse zur Bildgebung gastrointestinaler Stromatumoren und zur Bestimmung der Zielrezeptordichte im Gastrointestinaltrakt. Der Nuklearmediziner 2021;44:102-112. [DOI: 10.1055/a-1375-9605] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Faviana P, Boldrini L, Erba PA, Di Stefano I, Manassero F, Bartoletti R, Galli L, Gentile C, Bardi M. Gastrin-Releasing Peptide Receptor in Low Grade Prostate Cancer: Can It Be a Better Predictor Than Prostate-Specific Membrane Antigen? Front Oncol 2021;11:650249. [PMID: 33854977 DOI: 10.3389/fonc.2021.650249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
11 Palmioli A, Nicolini G, Tripodi F, Orsato A, Ceresa C, Donzelli E, Arici M, Coccetti P, Rocchetti M, La Ferla B, Airoldi C. Targeting GRP receptor: Design, synthesis and preliminary biological characterization of new non-peptide antagonists of bombesin. Bioorg Chem 2021;109:104739. [PMID: 33626451 DOI: 10.1016/j.bioorg.2021.104739] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Ciaffaglione V, Waghorn PA, Exner RM, Cortezon-Tamarit F, Godfrey SP, Sarpaki S, Quilter H, Dondi R, Ge H, Kociok-Kohn G, Botchway SW, Eggleston IM, Dilworth JR, Pascu SI. Structural Investigations, Cellular Imaging, and Radiolabeling of Neutral, Polycationic, and Polyanionic Functional Metalloporphyrin Conjugates. Bioconjug Chem 2021;32:1374-92. [PMID: 33525868 DOI: 10.1021/acs.bioconjchem.0c00691] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
13 Baun C, Mitran B, Rinne SS, Dam JH, Olsen BB, Tolmachev V, Orlova A, Thisgaard H. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. Molecules 2020;25:E5993. [PMID: 33352838 DOI: 10.3390/molecules25245993] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Judmann B, Braun D, Wängler B, Schirrmacher R, Fricker G, Wängler C. Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy. Pharmaceuticals (Basel) 2020;13:E173. [PMID: 32751666 DOI: 10.3390/ph13080173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
15 Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 2020;19:589-608. [PMID: 32728208 DOI: 10.1038/s41573-020-0073-9] [Cited by in Crossref: 160] [Cited by in F6Publishing: 169] [Article Influence: 53.3] [Reference Citation Analysis]
16 Kurmi BD, Patel P, Paliwal R, Paliwal SR. Molecular approaches for targeted drug delivery towards cancer: A concise review with respect to nanotechnology. Journal of Drug Delivery Science and Technology 2020;57:101682. [DOI: 10.1016/j.jddst.2020.101682] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
17 Hoppenz P, Els-Heindl S, Kellert M, Kuhnert R, Saretz S, Lerchen HG, Köbberling J, Riedl B, Hey-Hawkins E, Beck-Sickinger AG. A Selective Carborane-Functionalized Gastrin-Releasing Peptide Receptor Agonist as Boron Delivery Agent for Boron Neutron Capture Therapy. J Org Chem 2020;85:1446-57. [PMID: 31813224 DOI: 10.1021/acs.joc.9b02406] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
18 Hoppenz P, Els‐heindl S, Beck‐sickinger AG. Identification and stabilization of a highly selective gastrin‐releasing peptide receptor agonist. J Pep Sci 2019;25. [DOI: 10.1002/psc.3224] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]